Dalbavancin Sequential Therapy Tied To Earlier Hospital Discharge For Patients With Gram-Positive Bloodstream Infections, Study Finds

Infectious Disease Advisor (4/3, Barowski) reports, “Dalbavancin may facilitate earlier hospital discharge in patients with gram-positive bloodstream infections (BSIs) when administered as sequential therapy, according to study results published in Infectious Diseases and Therapy.” In the study, “further analysis at 80 days also showed low rates of mortality (7.0%), infection recurrence (3.5%), and treatment failure (7.8%) among the” treatment group.